Indivior Pharmaceuticals, Inc. (INDV): restructuring charge — Indivior estimates $105-130M restructuring charges; exits six non-US markets

Indivior Pharmaceuticals, Inc.

Total pre-tax restructuring charges estimated at $105-130M, with $65M recognized in Q3 2025.
Plans to exit markets: UK, Ireland, Sweden, Israel, Finland, Italy under Action Agenda Phase I.
Expects at least $150M annual operating expense savings starting in 2026.
Cash portion of charges $73-92M; includes severance, real estate, asset impairments, contract terminations.
Headcount reductions cost $33-37M; real estate consolidation $15-21M; asset impairments $21-27M.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $25 to $28 million affecting enterprise-wide.

Type: restructuring
Charge: approximately $25 to $28 million
Affected area: enterprise-wide

Exact text from the filing

The Company expects pre-tax cash and non-cash asset charges of approximately $25 to $28 million resulting from the termination of certain contracts.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $33 to $37 million affecting enterprise-wide.

Type: restructuring
Charge: approximately $33 to $37 million
Affected area: enterprise-wide

Exact text from the filing

The Company expects pre-tax employee severance and related employee exit charges of approximately $33 to $37 million, of which $17 million was recognized in the third quarter of 2025.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Indivior Pharmaceuticals, Inc. announced a impairment with charges of approximately $21 to $27 million affecting enterprise-wide.

Type: impairment
Charge: approximately $21 to $27 million
Affected area: enterprise-wide

Exact text from the filing

The Company expects pre-tax cash and non-cash asset charges of approximately $21 to $27 million resulting from the write-downs of intangible assets and inventory.

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Indivior Pharmaceuticals, Inc. announced a restructuring with charges of approximately $15 to $21 million affecting real estate.

Type: restructuring
Charge: approximately $15 to $21 million
Affected area: real estate

Exact text from the filing

The Company expects pre-tax cash and non-cash asset charges of approximately $15 to $21 million resulting from the consolidation and exit of certain real estate properties, including write-downs of leasehold improvements, fixed assets, and acceleration of leased property restoration costs.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Indivior Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001625297-25-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.